Amgen Inc., et al., Petitioners v. Sanofi, et al.

  1. December 13, 2023

    The Biggest Patent Rulings Of 2023

    Over the past year, the Federal Circuit has suspended one of its own judges, Delaware's chief federal judge has told the U.S. Department of Justice to investigate attorneys practicing in his court, and the Federal Circuit vacated a huge infringement verdict. Here's what you need to know about these cases and other major decisions in 2023.

  2. July 17, 2023

    The Biggest Patent Rulings Of 2023: A Midyear Report

    In the first six months of the year, the U.S. Supreme Court imposed limits on broadly written patents, while the Federal Circuit set rules on when inter partes reviews limit invalidity arguments in court. Here's a look at the most notable patent rulings of 2023, so far.

  3. May 22, 2023

    What IP Attys Should Know About Enablement After Amgen

    The same patent enablement standard that has existed for centuries must be applied to modern antibody patents, the U.S. Supreme Court ruled last week, prompting attorneys to review current patents and applications and look closely at enablement in litigation and prosecution.

  4. May 18, 2023

    Justices Clamp Down On Broad Patents In Amgen Decision

    The U.S. Supreme Court sent a clear message Thursday that broad patents covering anything that can perform a certain function are not allowed, meaning patent applications must be tailored more narrowly to what has been discovered, particularly in the biotechnology field, attorneys say.

  5. May 18, 2023

    Sanofi Wins Patent Enablement Fight At Supreme Court

    The U.S. Supreme Court on Thursday held that a patent covering a class of processes must provide enough information allowing people to replicate the full scope of the invention, providing a win for Sanofi and Regeneron Pharmaceuticals in a dispute over Amgen antibody patents. 

  6. March 27, 2023

    Justices Experiment With Enablement Paths In Amgen IP Row

    The U.S. Supreme Court justices on Monday seemed confused as they grappled for more than an hour and a half over how many antibodies are actually covered by Amgen patents underlying the cholesterol drug Repatha, and how much experimentation it would take to reach the patents' full scope.

  7. March 24, 2023

    Amgen Supreme Court Arguments Aren't Just About Biology

    The lone patent case the U.S. Supreme Court has agreed to hear this term centers on how pharmaceutical companies claim antibodies in patents and the way that impacts competing cholesterol medications, meaning a decision will clearly have implications for attorneys in the life sciences area. But lawyers who focus on software and other sectors should be paying attention as well.

  8. March 24, 2023

    Up Next At High Court: Inducing Migration, Speech Or Crime?

    This week, the U.S. Supreme Court will hear a major patent battle between pharmaceutical giants, as well as a challenge to a statute making it a crime to encourage illegal immigration that has vexed the justices in recent years.

  9. March 23, 2023

    What To Know Before Justices Take On Patent Enablement

    The U.S. Supreme Court on Monday will look into what the standard should be for patents to be enabled, in a dispute pitting major players in the pharmaceutical industry against each other. Here's what you need to know about the case.

  10. March 07, 2023

    Amgen Says Sanofi Contradicting Itself In High Court IP Feud

    Biotechnology giant Amgen has urged the U.S. Supreme Court not to "distort enablement law" as justices review a Federal Circuit decision axing patents on its cholesterol drug Repatha, arguing that Sanofi is a walking contradiction when it comes to the patent challenger's stance on enablement requirements.